bortezomib
Showing 1 - 25 of 559
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Bortezomib)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Bortezomib
-
Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
Sep 7, 2023
Rheumatoid Arthritis Trial in Beijing (bortezomib)
Not yet recruiting
- Rheumatoid Arthritis
- bortezomib
-
Beijing, ChinaPeking Union Medical College Hospital
Apr 6, 2023
Bortezomib, Glomerulonephritis, MN Trial in Shanghai (Bortezomib)
Recruiting
- Bortezomib
- +5 more
- Bortezomib
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Oct 28, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
- Bortezomib
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Alvocade® (Bortezomib) Safety and Effectiveness Study
Completed
- Multiple Myeloma, Refractory
- Bortezomib
- (no location specified)
Aug 19, 2023
Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult Trial in Indianapolis
Not yet recruiting
- Bone Marrow Transplant Complications
- +4 more
- Sitagliptin
- +2 more
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
May 30, 2023
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)
Not yet recruiting
- Relapsed/Refractory Immune Thrombocytopenia
- Bortezomib
-
Seoul, Korea, Republic of
- +1 more
Oct 30, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Multiple Myeloma Trial in Hackensack (Bortezomib)
Terminated
- Multiple Myeloma
- Bortezomib
-
Hackensack, New JerseyThe Cancer Center at Hackensack University Medical Center
Jun 24, 2022
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca Trial run by the National Heart, Lung, and Blood Institute
Completed
- Chronic Myeloid Leukemia (CML)
- +4 more
- Bortezomib
- NK cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 31, 2022
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Multiple Myeloma Trial in Rionero in Vulture (Bortezomib, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- Dexamethasone
-
Rionero in Vulture, Potenza, ItalyIrccs Crob
Mar 24, 2022
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Auto Stem Cell Transplant
- Bortezomib
-
Hackensack, New JerseyJohn Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022
Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Myeloma
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Sep 5, 2022
Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)
Active, not recruiting
- Amyloidosis; Systemic
- Daratumumab
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 9, 2022
Antibody-mediated Rejection Trial in Tehran (Bortezomib)
Recruiting
- Antibody-mediated Rejection
- Bortezomib
-
Tehran, Iran, Islamic Republic ofSBMU
Jan 27, 2022
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023